XORTX Therapeutics (XORTX Therapeutics) Total Stockholders Equity : $6.09 Mil (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is XORTX Therapeutics Total Stockholders Equity?

XORTX Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $6.09 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. XORTX Therapeutics's Book Value per Share for the quarter that ended in Sep. 2023 was $3.04. The ratio of a company's debt over equity can be used to measure how leveraged this company is. XORTX Therapeutics's Debt-to-Equity for the quarter that ended in Sep. 2023 was 0.00.

XORTX Therapeutics Total Stockholders Equity Historical Data

The historical data trend for XORTX Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Total Stockholders Equity Chart

XORTX Therapeutics Annual Data

Trend

Feb15

Feb16

Feb17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Stockholders Equity

Get a 7-Day Free Trial

0.24

-0.16

0.99

13.13

6.98

XORTX Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Stockholders Equity	Get a 7-Day Free Trial															7.83	6.98	9.06	7.40	6.09

XORTX Therapeutics (NAS:XRTX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

XORTX Therapeutics's Book Value per Share for the quarter that ended in Sep. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(6.086	-	0)	/	1.99885
	=	3.04

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

XORTX Therapeutics's Debt-to-Equity for the quarter that ended in Sep. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.029	+	0)	/	6.086
	=	0.00

XORTX Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

XORTX Therapeutics (XORTX Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (NAS:XRTX) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

ANUA:Germany XRTX:Canada

Address

3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1

Website

https://www.xortx.com

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.